Pub Date : 2025-02-01DOI: 10.1016/j.jfo.2024.104380
R. Alvarado-Villacorta, N. Ramos-Betancourt, J.H. Davila-Alquisiras, K.A. Vazquez-Romo
<div><h3>Purpose</h3><div>To evaluate the clinical outcomes of topical 5-fluorouracil (5-FU) 1% as first-line therapy for giant ocular surface squamous neoplasia (OSSN).</div></div><div><h3>Materials and methods</h3><div>This was a non-comparative cohort study. We included patients with biopsy-proven giant OSSN in a tertiary-care setting. Giant OSSN was defined as a single lesion<!--> <!-->≥<!--> <!-->15<!--> <!-->mm in the largest basal dimension or an extent of<!--> <!-->≥<!--> <!-->6 clock hours of limbal involvement. Topical 5-FU 1% was administered QID for one week, followed by a three-week drug holiday. This treatment cycle was repeated until resolution. Resolution rate was the primary outcome measure, where complete resolution was defined clinically and by tomography. Secondary outcomes were time to resolution and frequency of recurrence and side effects.</div></div><div><h3>Results</h3><div>Twenty-seven eyes (27 patients) were included; the majority (19, 70%) were men, with a mean age of 69.2<!--> <!-->±<!--> <!-->15.7 years. Corneal/conjunctival intraepithelial neoplasia was diagnosed in 88%, and squamous cell carcinoma (SCC) in the remaining 12% of cases. The rate of complete resolution was 77.8% (21/27) after a mean of 5.1<!--> <!-->±<!--> <!-->2.1 cycles. The median time to complete resolution was 5 months (CI95% 4–6 months). During a mean follow-up of 10.2<!--> <!-->±<!--> <!-->2.9 months, recurrence was observed in one patient (4.8%) and four (14.8%) reported side effects. Patients with partial resolution were older and had a higher frequency of SCC diagnosis than those with complete resolution.</div></div><div><h3>Conclusion</h3><div>Topical 5-FU 1% appears to be useful as first-line therapy for giant OSSN, with good tolerance and a low frequency of recurrence. More studies with larger sample sizes and longer follow-up are needed.</div></div><div><h3>Objectif</h3><div>Évaluer les résultats cliniques du 5-fluorouracile (5-FU) topique à 1 % comme traitement de première intention des néoplasies squameuses géantes de la surface oculaire (OSSN).</div></div><div><h3>Matériel et méthodes</h3><div>Étude de cohorte non comparative. Nous avons inclus des patients atteints d’un OSSN géant prouvé par biopsie dans un établissement de soins tertiaires. L’OSSN géant est défini comme une lésion unique<!--> <!-->≥<!--> <!-->15<!--> <!-->mm au niveau du plus grand diamètre basal ou une étendue<!--> <!-->≥<!--> <!-->6<!--> <!-->heures d’horloge de l’atteinte limbique. Le 5-FU topique à 1 % a été administré quatre fois par jour pendant une semaine, suivie d’une pause de trois semaines. Ce cycle de traitement a été répété jusqu’à la résolution. Le taux de résolution était le principal critère de jugement, la résolution complète étant définie comme l’absence de lésions sur le plan clinique et tomographique. Les résultats secondaires étaient le délai de résolution et la fréquence des récidives et des effets secondaires.</div></div><div><h3>Résultats</h3>
{"title":"Topical 5-fluorouracil 1% as first-line therapy for giant ocular surface squamous neoplasia","authors":"R. Alvarado-Villacorta, N. Ramos-Betancourt, J.H. Davila-Alquisiras, K.A. Vazquez-Romo","doi":"10.1016/j.jfo.2024.104380","DOIUrl":"10.1016/j.jfo.2024.104380","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the clinical outcomes of topical 5-fluorouracil (5-FU) 1% as first-line therapy for giant ocular surface squamous neoplasia (OSSN).</div></div><div><h3>Materials and methods</h3><div>This was a non-comparative cohort study. We included patients with biopsy-proven giant OSSN in a tertiary-care setting. Giant OSSN was defined as a single lesion<!--> <!-->≥<!--> <!-->15<!--> <!-->mm in the largest basal dimension or an extent of<!--> <!-->≥<!--> <!-->6 clock hours of limbal involvement. Topical 5-FU 1% was administered QID for one week, followed by a three-week drug holiday. This treatment cycle was repeated until resolution. Resolution rate was the primary outcome measure, where complete resolution was defined clinically and by tomography. Secondary outcomes were time to resolution and frequency of recurrence and side effects.</div></div><div><h3>Results</h3><div>Twenty-seven eyes (27 patients) were included; the majority (19, 70%) were men, with a mean age of 69.2<!--> <!-->±<!--> <!-->15.7 years. Corneal/conjunctival intraepithelial neoplasia was diagnosed in 88%, and squamous cell carcinoma (SCC) in the remaining 12% of cases. The rate of complete resolution was 77.8% (21/27) after a mean of 5.1<!--> <!-->±<!--> <!-->2.1 cycles. The median time to complete resolution was 5 months (CI95% 4–6 months). During a mean follow-up of 10.2<!--> <!-->±<!--> <!-->2.9 months, recurrence was observed in one patient (4.8%) and four (14.8%) reported side effects. Patients with partial resolution were older and had a higher frequency of SCC diagnosis than those with complete resolution.</div></div><div><h3>Conclusion</h3><div>Topical 5-FU 1% appears to be useful as first-line therapy for giant OSSN, with good tolerance and a low frequency of recurrence. More studies with larger sample sizes and longer follow-up are needed.</div></div><div><h3>Objectif</h3><div>Évaluer les résultats cliniques du 5-fluorouracile (5-FU) topique à 1 % comme traitement de première intention des néoplasies squameuses géantes de la surface oculaire (OSSN).</div></div><div><h3>Matériel et méthodes</h3><div>Étude de cohorte non comparative. Nous avons inclus des patients atteints d’un OSSN géant prouvé par biopsie dans un établissement de soins tertiaires. L’OSSN géant est défini comme une lésion unique<!--> <!-->≥<!--> <!-->15<!--> <!-->mm au niveau du plus grand diamètre basal ou une étendue<!--> <!-->≥<!--> <!-->6<!--> <!-->heures d’horloge de l’atteinte limbique. Le 5-FU topique à 1 % a été administré quatre fois par jour pendant une semaine, suivie d’une pause de trois semaines. Ce cycle de traitement a été répété jusqu’à la résolution. Le taux de résolution était le principal critère de jugement, la résolution complète étant définie comme l’absence de lésions sur le plan clinique et tomographique. Les résultats secondaires étaient le délai de résolution et la fréquence des récidives et des effets secondaires.</div></div><div><h3>Résultats</h3>","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 2","pages":"Article 104380"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142818087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.jfo.2024.104381
L. Doğan , Z. Özer Özcan , İ. Edhem Yılmaz
<div><h3>Purpose</h3><div>To evaluate the appropriateness, understandability, actionability, and readability of responses provided by ChatGPT-3.5, Bard, and Bing Chat to frequently asked questions about keratorefractive surgery (KRS).</div></div><div><h3>Method</h3><div>Thirty-eight frequently asked questions about KRS were directed three times to a fresh ChatGPT-3.5, Bard, and Bing Chat interfaces. Two experienced refractive surgeons categorized the chatbots’ responses according to their appropriateness and the accuracy of the responses was assessed using the Structure of the Observed Learning Outcome (SOLO) taxonomy. Flesch Reading Ease (FRE) and Coleman-Liau Index (CLI) were used to evaluate the readability of the responses of chatbots. Furthermore, the understandability scores of responses were evaluated using the Patient Education Materials Assessment Tool (PEMAT).</div></div><div><h3>Results</h3><div>The appropriateness of the ChatGPT-3.5, Bard, and Bing Chat responses was 86.8% (33/38), 84.2% (32/38), and 81.5% (31/38), respectively (<em>P</em> <!-->><!--> <!-->0.05). According to the SOLO test, ChatGPT-3.5 (3.91<!--> <!-->±<!--> <!-->0.44) achieved the highest mean accuracy and followed by Bard (3.64<!--> <!-->±<!--> <!-->0.61) and Bing Chat (3.19<!--> <!-->±<!--> <!-->0.55). For understandability (mean PEMAT-U score the ChatGPT-3.5: 68.5%, Bard: 78.6%, and Bing Chat: 67.1%, <em>P</em> <!--><<!--> <!-->0.05), and actionability (mean PEMAT-A score the ChatGPT-3.5: 62.6%, Bard: 72.4%, and Bing Chat: 60.9%, <em>P</em> <!--><<!--> <!-->0.05) the Bard scored better than the other chatbots. Two readability analyses showed that Bing had the highest readability, followed by the ChatGPT-3.5 and Bard, however, the understandability and readability scores were more challenging than the recommended level.</div></div><div><h3>Conclusion</h3><div>Artificial intelligence supported chatbots have the potential to provide detailed and appropriate responses at acceptable levels in KRS. Chatbots, while promising for patient education in KRS, require further progress, especially in readability and understandability aspects.</div></div><div><h3>Objectif</h3><div>Évaluer la pertinence, la compréhensibilité, l’applicabilité et la lisibilité des réponses fournies par ChatGPT-3.5, Bard et Bing Chat aux questions fréquemment posées sur la chirurgie kératoréfractive (CKR).</div></div><div><h3>Méthode</h3><div>Trente-huit questions fréquemment posées sur la CKR ont été adressées trois fois à des interfaces de ChatGPT-3.5, Bard et Bing Chat. Deux chirurgiens réfractifs expérimentés ont catégorisé les réponses des chatbots selon leur pertinence et l’exactitude des réponses a été évaluée à l’aide de la taxonomie SOLO (<em>Structure of the Observed Learning Outcome</em>). L’indice de facilité de lecture de Flesch (FRE) et l’indice de Coleman-Liau (CLI) ont été utilisés pour évaluer la lisibilité des réponses des chatbots. De plus, les scores de compréhensibilité
{"title":"The promising role of chatbots in keratorefractive surgery patient education","authors":"L. Doğan , Z. Özer Özcan , İ. Edhem Yılmaz","doi":"10.1016/j.jfo.2024.104381","DOIUrl":"10.1016/j.jfo.2024.104381","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the appropriateness, understandability, actionability, and readability of responses provided by ChatGPT-3.5, Bard, and Bing Chat to frequently asked questions about keratorefractive surgery (KRS).</div></div><div><h3>Method</h3><div>Thirty-eight frequently asked questions about KRS were directed three times to a fresh ChatGPT-3.5, Bard, and Bing Chat interfaces. Two experienced refractive surgeons categorized the chatbots’ responses according to their appropriateness and the accuracy of the responses was assessed using the Structure of the Observed Learning Outcome (SOLO) taxonomy. Flesch Reading Ease (FRE) and Coleman-Liau Index (CLI) were used to evaluate the readability of the responses of chatbots. Furthermore, the understandability scores of responses were evaluated using the Patient Education Materials Assessment Tool (PEMAT).</div></div><div><h3>Results</h3><div>The appropriateness of the ChatGPT-3.5, Bard, and Bing Chat responses was 86.8% (33/38), 84.2% (32/38), and 81.5% (31/38), respectively (<em>P</em> <!-->><!--> <!-->0.05). According to the SOLO test, ChatGPT-3.5 (3.91<!--> <!-->±<!--> <!-->0.44) achieved the highest mean accuracy and followed by Bard (3.64<!--> <!-->±<!--> <!-->0.61) and Bing Chat (3.19<!--> <!-->±<!--> <!-->0.55). For understandability (mean PEMAT-U score the ChatGPT-3.5: 68.5%, Bard: 78.6%, and Bing Chat: 67.1%, <em>P</em> <!--><<!--> <!-->0.05), and actionability (mean PEMAT-A score the ChatGPT-3.5: 62.6%, Bard: 72.4%, and Bing Chat: 60.9%, <em>P</em> <!--><<!--> <!-->0.05) the Bard scored better than the other chatbots. Two readability analyses showed that Bing had the highest readability, followed by the ChatGPT-3.5 and Bard, however, the understandability and readability scores were more challenging than the recommended level.</div></div><div><h3>Conclusion</h3><div>Artificial intelligence supported chatbots have the potential to provide detailed and appropriate responses at acceptable levels in KRS. Chatbots, while promising for patient education in KRS, require further progress, especially in readability and understandability aspects.</div></div><div><h3>Objectif</h3><div>Évaluer la pertinence, la compréhensibilité, l’applicabilité et la lisibilité des réponses fournies par ChatGPT-3.5, Bard et Bing Chat aux questions fréquemment posées sur la chirurgie kératoréfractive (CKR).</div></div><div><h3>Méthode</h3><div>Trente-huit questions fréquemment posées sur la CKR ont été adressées trois fois à des interfaces de ChatGPT-3.5, Bard et Bing Chat. Deux chirurgiens réfractifs expérimentés ont catégorisé les réponses des chatbots selon leur pertinence et l’exactitude des réponses a été évaluée à l’aide de la taxonomie SOLO (<em>Structure of the Observed Learning Outcome</em>). L’indice de facilité de lecture de Flesch (FRE) et l’indice de Coleman-Liau (CLI) ont été utilisés pour évaluer la lisibilité des réponses des chatbots. De plus, les scores de compréhensibilité","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 2","pages":"Article 104381"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.jfo.2024.104373
Y. Rivoal , A. Miguel , H. Bailleul , M. Canino , S. Bacon , G. Saint-Lorant , É. Deloison , J.-C. Quintyn
<div><div>Dry eye syndrome is a multifactorial disease with a complex pathophysiology. The associated morbidity is a worldwide public health problem. The development of autologous serum-based eye drops is an interesting treatment but presents some constraints. This is a retrospective, observational, single-center study of 43 patients (73 eyes) treated with autologous serum-based eye drops for dry eye syndrome at the University Hospital of Caen between 2014 and 2023. The patients’ subjective symptoms, as well as the various modalities of evaluation of their daily quality of life were collected using questionnaires inspired by the OSDI questionnaire. The other elements used in this study were reported from the patients’ medical files. We observed a mean improvement in quality of life of 44% in the treated subjects. Quality of life correlates with the improvement in the subject's quality of life score and overall health (<em>P</em> <!--><<!--> <!-->0.01) but, nevertheless, depends on the severity of the initial clinical damage and the presence or absence of a corneal ulcer (<em>P</em> <!-->=<!--> <!-->0.013). We also found a reduction in the number of daily drops (65.4%) and an improvement in daily activities (85.1%). This study's results are consistent with previous work reporting the efficacy of autologous serum on the quality of life of treated patients. Consideration of the patient as a whole, integrating quality of life assessment with clinical examination, is essential when dealing with dry eye and its innovative therapeutics.</div></div><div><div>Le syndrome de l’œil sec est une maladie multifactorielle avec une pathophysiologie complexe. La morbidité associée est un problème de santé publique mondial. Le développement de gouttes oculaires à base de sérum autologue est un traitement intéressant, mais présente certaines contraintes. Il s’agit d’une étude rétrospective et d’observation, menée dans un seul centre, portant sur 43 patients (73 yeux) traités avec des gouttes oculaires à base de sérum autologue pour le syndrome de l’œil sec à l’hôpital universitaire de Caen entre 2014 et 2023. Les symptômes subjectifs des patients, ainsi que les différentes modalités d’évaluation de leur qualité de vie quotidienne, ont été recueillis à l’aide de questionnaires inspirés du questionnaire OSDI. Les autres éléments utilisés dans cette étude ont été rapportés à partir des dossiers médicaux des patients. Nous avons observé une amélioration moyenne de la qualité de vie de 44 % chez les sujets traités. La qualité de vie est corrélée avec l’amélioration du score de qualité de vie des sujets et de leur santé globale (<em>p</em> <!--><<!--> <!-->0,01), mais dépend néanmoins de la gravité des lésions cliniques initiales et de la présence ou de l’absence d’un ulcère cornéen (<em>p</em> <!-->=<!--> <!-->0,013). Nous avons également constaté une réduction du nombre de gouttes administrées quotidiennement (65,4 %) et une amélioration des activités quotidienne
{"title":"Study of quality of life in patients treated with autologous serum eye drops","authors":"Y. Rivoal , A. Miguel , H. Bailleul , M. Canino , S. Bacon , G. Saint-Lorant , É. Deloison , J.-C. Quintyn","doi":"10.1016/j.jfo.2024.104373","DOIUrl":"10.1016/j.jfo.2024.104373","url":null,"abstract":"<div><div>Dry eye syndrome is a multifactorial disease with a complex pathophysiology. The associated morbidity is a worldwide public health problem. The development of autologous serum-based eye drops is an interesting treatment but presents some constraints. This is a retrospective, observational, single-center study of 43 patients (73 eyes) treated with autologous serum-based eye drops for dry eye syndrome at the University Hospital of Caen between 2014 and 2023. The patients’ subjective symptoms, as well as the various modalities of evaluation of their daily quality of life were collected using questionnaires inspired by the OSDI questionnaire. The other elements used in this study were reported from the patients’ medical files. We observed a mean improvement in quality of life of 44% in the treated subjects. Quality of life correlates with the improvement in the subject's quality of life score and overall health (<em>P</em> <!--><<!--> <!-->0.01) but, nevertheless, depends on the severity of the initial clinical damage and the presence or absence of a corneal ulcer (<em>P</em> <!-->=<!--> <!-->0.013). We also found a reduction in the number of daily drops (65.4%) and an improvement in daily activities (85.1%). This study's results are consistent with previous work reporting the efficacy of autologous serum on the quality of life of treated patients. Consideration of the patient as a whole, integrating quality of life assessment with clinical examination, is essential when dealing with dry eye and its innovative therapeutics.</div></div><div><div>Le syndrome de l’œil sec est une maladie multifactorielle avec une pathophysiologie complexe. La morbidité associée est un problème de santé publique mondial. Le développement de gouttes oculaires à base de sérum autologue est un traitement intéressant, mais présente certaines contraintes. Il s’agit d’une étude rétrospective et d’observation, menée dans un seul centre, portant sur 43 patients (73 yeux) traités avec des gouttes oculaires à base de sérum autologue pour le syndrome de l’œil sec à l’hôpital universitaire de Caen entre 2014 et 2023. Les symptômes subjectifs des patients, ainsi que les différentes modalités d’évaluation de leur qualité de vie quotidienne, ont été recueillis à l’aide de questionnaires inspirés du questionnaire OSDI. Les autres éléments utilisés dans cette étude ont été rapportés à partir des dossiers médicaux des patients. Nous avons observé une amélioration moyenne de la qualité de vie de 44 % chez les sujets traités. La qualité de vie est corrélée avec l’amélioration du score de qualité de vie des sujets et de leur santé globale (<em>p</em> <!--><<!--> <!-->0,01), mais dépend néanmoins de la gravité des lésions cliniques initiales et de la présence ou de l’absence d’un ulcère cornéen (<em>p</em> <!-->=<!--> <!-->0,013). Nous avons également constaté une réduction du nombre de gouttes administrées quotidiennement (65,4 %) et une amélioration des activités quotidienne","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 2","pages":"Article 104373"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.jfo.2024.104362
J.-C. Liu, S.-J. Zhang, X.-M. Yan, W.-B. Zhang
{"title":"Spontaneous partial resolution of retinal detachment in a child with morning glory syndrome","authors":"J.-C. Liu, S.-J. Zhang, X.-M. Yan, W.-B. Zhang","doi":"10.1016/j.jfo.2024.104362","DOIUrl":"10.1016/j.jfo.2024.104362","url":null,"abstract":"","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 2","pages":"Article 104362"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：